Notably, RAS and MYC are among the most commonly deregulated oncogenes in cancer, with RAS mutations being the most frequent2 and MYC the most amplified.3 Given their widespread alteration across various cancer types and their significant role in tumorigenesis, both MYC and RAS have garnered considerable attention as promising therapeutic targets. Here, MYC is linked to cancer.